Concordance between the genomic landscape identified by whole-exome sequencing of plasma cfDNA and tumor; DNA and recurrence of KDR/VEGFR2 oncogenic mutations in human cancers. Concordance between the genomic landscape identified by whole-exome sequencing of plasma cfDNA and tumor; DNA and recurrence of KDR/VEGFR2 oncogenic mutations in human cancers. A, The histograms represent all the genes with somatic mutations identified by plasma cfDNA whole-exome sequencing (in red) and by tumor whole-exome sequencing (in blue). The list and genomic annotation of all mutations are shown in SupplementaryTable S1. The mutated allele frequencies (MAFs) of each mutation in relation to all reads are depicted in Y. B, Copy number alteration landscape portrayed by the whole-exome sequencing of tumor DNA (upper part) and pre-treatment plasma cfDNA (lower part). Gains are depicted in green, losses in red, and normal (balanced) in grey. C, Frequency of KDR somatic mutations in large cancer genomic sequencing projects including more than 70,000 cancer samples. Common germline polymorphisms were excluded from these analyses and only cancer-exclusive mutations were considered. D, Representative results from the search of genomics and protein databases, showing several mutations, structurally analogous to those of KDR, identified in other cancer-relevant kinases. Rodrigo A. Toledo et al. Clin Cancer Res 2018;24:3550-3559 ©2018 by American Association for Cancer Research